Recombinant Human G-CSF/CSF3 Protein (Fc Tag)(Active)
| Code | Size | Price |
|---|
| PKSH031938-100ug | 100ug | £972.00 |
Quantity:
| PKSH031938-1mg | 1mg | £5,831.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Human
Regulatory Status: RUO
Application: Cell Culture
Shipping:
This product is provided as lyophilized powder which is shipped with ice packs.
Storage:
Samples are stable for up to twelve months from date of receipt at -70°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Further Information
Abbreviation:
G-CSF;CSF3
Accession:
NP_75737°C.1
Activity:
Measured in a cell proliferation assay using a murine myeloblastic cell line, NFS-60.The ED50 for this effect is typically 0.2-0.8 ng/ml.
Background:
Granulocyte-colony stimulating factor (G-CSF) is a growth factor and an essential cytokine belonging to the CSF family of hormone-like glycoproteins. It is produced by numerous cell types including immune and endothelial cells. Recent animal studies have also revealed that G-CSF activates multiple signaling pathways, such as Akt and also the Janus family kinase-2 and signal transducer and activation of transcription-3 (Jak2-STAT3) pathway, thereby promoting survival, proliferation, differentiation and mobilisation of haematopoietic stem and progenitor cells. G-CSF is a cytokine that have been demonstrated to improve cardiac function and perfusion in myocardial infarction. And it was initially evaluated as a stem cell mobilizer and erythropoietin as a cytoprotective agent. G-CSF prevents left ventricular remodeling after myocardial infarction by decreasing cardiomyocyte death and by increasing the number of blood vessels, suggesting the importance of direct actions of G-CSF on the myocardium rather than through mobilization and differentiation of stem cells. Accordingly, recombinant human (rh)G-CSF has been extensively used in clinical haematology and oncology to enable bone marrow transplantation or to treat chemotherapy-associated neutropenia. In preclinical study, G-CSF improved cardiac function and perfusion by angiomyogenesis and protection of cardiomyocytes in myocardial infarction.
Calculated MW:
45.4 kDa
Endotoxin:
< 1.0 EU per ug of the protein as determined by the LAL method.
Expression Host:
HEK293 Cells
Formulation:
Lyophilized from sterile 100mM Glycine, 10mM NaCl, 50mM Tris, pH 7.5
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Fusion tag:
N-hFc
ObservedMW:
48 kDa
Purity:
> 97 % as determined by reducing SDS-PAGE.
Sequence:
Ala 30-Pro 204
Target Synonym:
Granulocyte Colony-Stimulating Factor;G-CSF;Pluripoietin;Filgrastim;Lenograstim;CSF3;C17orf33;GCSF